Biophore receives sub-license to manufacture Molnupiravir

20-01-2022 Thu 23:06 IST | IANS | Health
Biophore receives sub-license to manufacture Molnupiravir

Hyderabad, Jan 20:  Biophore India Pharmaceuticals on Thursday announced that it has received license from Medicines Patent Pool (MPP) on behalf of originator company MSD, a trade name of Merck to manufacture and market Molnupiravir API and finished product in capsule form.

The Hyderabad-based company said that the development of the product is complete and is gearing up for launch based on this licence within the next one week. The licence received by Biophore enables the company to launch the product within India as well as export to 104 other countries around the world, the company said in a statement.

For the Indian market, the company has already received the relevant regulatory approvals from Drug Controller General of India (DCGI) and will be launching the product next week at one of the lowest prices currently in the market - Rs 1,500 for a pack of 40 capsules.

Molnupiravir is an oral antiviral approved through the emergency use authorisation route by the US Food and Drug Administration and UK authorities for treatment of mild to moderate Covid-19. Its effectiveness has been established through studies conducted across the world and is expected to significantly reduce hospitalisation of Covid-19 patients, if taken at an early stage. In India too, the DCGI has approved this product for the treatment of Covid-19 based on the review of clinical data available.

"Biophore has been at the forefront of the fight against Covid-19 and we are extremely proud of this fact. During the earlier wave, we had successfully scaled up and commercialised Favipiravir, the antiviral approved during that time for Covid treatment, in record time. We are also the largest Indian manufacturers of SBECD, a vital ingredient for Remdesivir injection manufacturing and have also developed Nirmatrelvir, which is the active ingredient in the other US FDA approved oral Covid antiviral," said CEO Dr Jagadeesh Babu Rangisetty.

"Similarly, we are committed to bring Molnupiravir to the market in the shortest time possible complying to all quality and regulatory requirements - all our products are manufactured in US FDA approved facilities," he added.


More News
ICMR launches app for inflammatory bowel disease
4 hours ago
Telangana CM congratulates Nikhat Zareen
5 hours ago
'Tarbooz politics' in Pak: Politician distributes watermelons with his name carved on them
5 hours ago
RCB fans create Guinness World Record for Most Cricket Runs between the wickets in an hour
5 hours ago
Aishwarya Rai Bachchan dazzles in D&G
5 hours ago
PM Modi to visit Tokyo to attend Quad Summit
5 hours ago
Women's World Boxing: Nikhat strikes gold, becomes 5th Indian woman to bag yellow metal at Worlds
5 hours ago
'F3' producer Dil Raju to go with low ticket prices for his film
7 hours ago
'SVP' director's defence of controversial scene faces backlash
8 hours ago
'Hand can also be weapon': SC on 1-year rigorous imprisonment for Navjot Singh Sidhu
8 hours ago
Sequel to Nandamuri Balakrisha-Boypati Sreenu 'Akhanda' is on the cards
9 hours ago
Natural Star Nani likely to team up with Super Star Mahesh Babu in Trivikam's movie
9 hours ago
Bindhu Madhavi, Akhil Sarthak in the race to bag Big Boss OTT trophy
9 hours ago
Andhra Pradesh CM flags off 175 veterinary ambulances
10 hours ago
BCs in TDP only for photo-op: Beeda Mastan Rao
10 hours ago
Jr NTR, Koratala Siva pre-look poster out, film to be an action mass entertainer
10 hours ago
Putin's daughter Katerina's lover is called Zelensky
10 hours ago
206 kidney stones removed from man in Hyderabad
10 hours ago
Will submit to majesty of law, says Sidhu on one-year jail term
11 hours ago
PM's Hyderabad visit to rev up Telangana BJP
11 hours ago